Although ligelizumab as an IgE inhibitor showed a reduction in the hive severity score (HSS) and itch severity score (ISS) comparable to omalizumab in the phase III study, it was not superior to omalizumab, which is why the focus is currently on possible use in the area of food allergies or chronic inducible urticaria [216, 217]. Here, IGHE is linked to food allergy.